{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:16:16Z","timestamp":1782209776520,"version":"3.54.5"},"reference-count":52,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To detect spondyloarthritis (SpA) and evaluate risk factors in patients with inflammatory bowel disease (IBD) during biologic or Janus kinase inhibitor (JAKi) treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study of patients with IBD receiving biologics or JAKi, excluding prior SpA cases. We identified patients who developed musculoskeletal (MSK) symptoms during IBD treatment. SpA was diagnosed after a clinical evaluation by a rheumatologist alongside imaging analysis of conventional radiographs and HLA-B27 determination. Magnetic resonance imaging of the sacroiliac joints was performed only in cases where the conventional radiograph was inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1649 patients with IBD receiving biologic or JAKi treatment (Crohn disease: 1335; ulcerative colitis [UC]: 314), 96 (5.8%) were excluded due to a prior SpA diagnosis. Among the remaining 1553 patients, 106 (6.8%) developed MSK symptoms during IBD treatment, and 30 (1.9%) were diagnosed with SpA (axial: 20; peripheral: 10) during the follow-up (median 5.2 [IQR 3.4-7.5] years). Risk factors for SpA in these patients included a partial Mayo score for UC at the time of onset of MSK symptoms (hazard ratio [HR] 1.57;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.03) and HLA-B27 positivity (HR 3.70;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004). As well as IBD treatment, 23\/30 (77%) patients with SpA used nonsteroidal antiinflammatory drugs (NSAIDs). IBD disease activity did not worsen during treatment, regardless of NSAID use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>During a median follow-up of 5.2 years, 6.8% of patients with IBD undergoing biologic or JAKi treatment developed MSK symptoms, with one-third subsequently diagnosed with SpA. HLA-B27 positivity and higher UC disease activity were associated with an increased risk of SpA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2024-1279","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:20:12Z","timestamp":1753446012000},"page":"260-270","source":"Crossref","is-referenced-by-count":2,"title":["Risk of Spondyloarthritis in Patients With Inflammatory Bowel Disease Receiving Treatment With Biologics or Janus Kinase Inhibitors"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-5388","authenticated-orcid":false,"given":"Young-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-9768","authenticated-orcid":false,"given":"Soo Min","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0205-6492","authenticated-orcid":false,"given":"Ji Seon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-7355","authenticated-orcid":false,"given":"Yong-Gil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-7515","authenticated-orcid":false,"given":"Chang-Keun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-5273","authenticated-orcid":false,"given":"Bin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-7575","authenticated-orcid":false,"given":"Sung Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-6325","authenticated-orcid":false,"given":"Byong Duk","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2772-2575","authenticated-orcid":false,"given":"Suk-Kyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-5749","authenticated-orcid":false,"given":"Sang Hyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8722-3124","authenticated-orcid":false,"given":"Seokchan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2026032910412620000_53.3.260.1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i22.2702"},{"key":"2026032910412620000_53.3.260.2","first-page":"631","article-title":"The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis","volume":"11","author":"Karreman","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026032910412620000_53.3.260.3","first-page":"511","article-title":"Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study)","volume":"29","author":"Palm","year":"2002","journal-title":"J Rheumatol"},{"key":"2026032910412620000_53.3.260.4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.2449"},{"key":"2026032910412620000_53.3.260.5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5217\/ir.2021.00139","article-title":"Long-term clinical and real-world experience with Crohn\u2019s disease treated with anti-tumor Necrosis Factor-alpha antibodies","volume":"20","author":"Otake","year":"2022","journal-title":"Intest Res"},{"key":"2026032910412620000_53.3.260.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170477"},{"key":"2026032910412620000_53.3.260.7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5217\/ir.2021.00037","article-title":"Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation","volume":"20","author":"Barberio","year":"2022","journal-title":"Intest Res"},{"key":"2026032910412620000_53.3.260.8","first-page":"e77363","article-title":"Paradoxical inflammatory bowel disease induced by golimumab in a patient with ankylosing spondylitis: a case report and systematic review","volume":"17","author":"Alnaqbi","year":"2025","journal-title":"Cureus"},{"key":"2026032910412620000_53.3.260.9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000667"},{"key":"2026032910412620000_53.3.260.10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155812"},{"key":"2026032910412620000_53.3.260.11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5217\/ir.2014.12.4.281","article-title":"Long-term clinical outcomes of Korean patient with Crohn\u2019s disease following early use of infliximab","volume":"12","author":"Kim","year":"2014","journal-title":"Intest Res"},{"key":"2026032910412620000_53.3.260.12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review","volume":"15","author":"Guillo","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026032910412620000_53.3.260.13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026032910412620000_53.3.260.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"2026032910412620000_53.3.260.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"2026032910412620000_53.3.260.16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MEG.0000000000002527","article-title":"Prevalence and predictors of arthralgia after initiation of vedolizumab in patients with inflammatory bowel disease: a retrospective cohort study","volume":"35","author":"Kokkotis","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026032910412620000_53.3.260.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210233"},{"key":"2026032910412620000_53.3.260.18","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/rheumatology\/keaa107","article-title":"Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab","volume":"59","author":"Dupr\u00e9","year":"2020","journal-title":"Rheumatology"},{"key":"2026032910412620000_53.3.260.19","unstructured":"Gordon H , Burisch J , Ellul P , ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2023:jjad108."},{"key":"2026032910412620000_53.3.260.20","doi-asserted-by":"crossref","first-page":"S761","DOI":"10.1093\/ecco-jcc\/jjaa003","article-title":"Janus kinase inhibitors in the new treatment paradigms of inflammatory bowel disease","volume":"14","author":"Siegmund","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026032910412620000_53.3.260.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601"},{"key":"2026032910412620000_53.3.260.22","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000441203.56196.46"},{"key":"2026032910412620000_53.3.260.23","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju017"},{"key":"2026032910412620000_53.3.260.24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1155\/1999\/506915","article-title":"The Crohn\u2019s disease activity index, its derivatives and the inflammatory bowel disease questionnaire: a review of instruments to assess in Crohn\u2019s disease","volume":"13","author":"Yoshida","year":"1999","journal-title":"Can J Gastroenterol"},{"key":"2026032910412620000_53.3.260.25","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"2026032910412620000_53.3.260.26","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.082909"},{"key":"2026032910412620000_53.3.260.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2026032910412620000_53.3.260.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208642"},{"key":"2026032910412620000_53.3.260.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2026032910412620000_53.3.260.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2026032910412620000_53.3.260.31","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2026032910412620000_53.3.260.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2014.10.018"},{"key":"2026032910412620000_53.3.260.33","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21248"},{"key":"2026032910412620000_53.3.260.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202545"},{"key":"2026032910412620000_53.3.260.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200828"},{"key":"2026032910412620000_53.3.260.36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the Gemini trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032910412620000_53.3.260.37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1124628"},{"key":"2026032910412620000_53.3.260.38","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ecco-jcc\/jjac058","article-title":"The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentre cohort study","volume":"16","author":"De Galan","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032910412620000_53.3.260.39","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from Phase 2\/3 studies","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026032910412620000_53.3.260.40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/rheumatology\/keae116","article-title":"Impact on patient outcomes of spondyloarthritis-inflammatory bowel disease multi-disciplinary meetings","volume":"64","author":"Sayers","year":"2025","journal-title":"Rheumatology"},{"key":"2026032910412620000_53.3.260.41","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199607000-00009"},{"key":"2026032910412620000_53.3.260.42","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i34.12269"},{"key":"2026032910412620000_53.3.260.43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MEG.0000000000001072","article-title":"Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications","volume":"30","author":"Herzog","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026032910412620000_53.3.260.44","doi-asserted-by":"publisher","DOI":"10.1080\/003655202760373362"},{"key":"2026032910412620000_53.3.260.45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00054725-199703000-00006","article-title":"Spondyloarthropathy and idiopathic inflammatory bowel diseases","volume":"3","author":"Meuwissen","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"2026032910412620000_53.3.260.46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03868.x"},{"key":"2026032910412620000_53.3.260.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.01.013"},{"key":"2026032910412620000_53.3.260.48","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200411000-00009"},{"key":"2026032910412620000_53.3.260.49","doi-asserted-by":"crossref","first-page":"599","DOI":"10.36076\/ppj.2015\/18\/599","article-title":"Coxib\u2019s safety in patients with inflammatory bowel diseases: a meta-analysis","volume":"18","author":"Ribaldone","year":"2015","journal-title":"Pain Physician"},{"key":"2026032910412620000_53.3.260.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02262.x"},{"key":"2026032910412620000_53.3.260.51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv195"},{"key":"2026032910412620000_53.3.260.52","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/apt.12680","article-title":"The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients","volume":"39","author":"Leclerc-Jacob","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2024-1279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T17:42:02Z","timestamp":1774806122000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2024-1279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.3899\/jrheum.2024-1279"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2024-1279","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}